Although first recognized as a rare clinical phenomenon, accumulating evidence has established SCLC transformation as a reproducible and clinically significant mechanism of resistance, characterized by retention of the initiating EGFR mutation, acquisition of neuroendocrine features, and aggressive clinical behavior. This evidence concerns the gene EGFR and small cell lung carcinoma.